Pure Global AI
NCT06225804Recruiting

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer
Abbisko Therapeutics Co, LtdPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-Small Cell Lung Cancer
Drug/Device/Intervention
ABSK112
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Abbisko Therapeutics Co, Ltd
Location
Beverly Hills,Hefei,Fuzhou,Xi'an,Harbin,Zhengzhou,Wuhan,Changsha,Nanchang,Changchun,Jinan,Shanghai,Chengdu,Hangzhou, China,United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Feb 22, 2024
End date
Mar 01, 2028
Enrollment
164 participants
Primary outcome

Incidence of DLT,AEs,AESIs,SAEs

Summary

This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of
 ABSK112 in patients with NSCLC to evaluate the safety, tolerability, PK, and preliminary
 antitumor efficacy.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06225804
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06225804 through Pure Global AI's free database. This Phase 1 trial is sponsored by Abbisko Therapeutics Co, Ltd and is currently Recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 164 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.